On March 12, Aimi Vaccine (06660) issued an announcement, announcing that its wholly-owned subsidiary Aimi Honor (Ningbo) Biopharmaceutical Co., Ltd. has completed the Phase III clinical trial of serum-free iterative rabies vaccine and obtained the corresponding production license. The vaccine will be submitted for drug registration, marking a major technological breakthrough in the field of rabies vaccines for the company, and is expected to become the world's first approved serum-free rabies vaccine.

According to the results of the completed Phase III clinical study, the vaccine showed good safety, immunogenicity and immune persistence, and has fully met the preset evaluation standards for clinical trials. At present, there is no serum-free rabies vaccine on the market in the world, and the main products sold in the market are serum rabies vaccines.

The serum-free iterative rabies vaccine developed by the company does not contain animal serum, which significantly improves safety and reduces the probability of adverse reactions. According to statistics from Frost & Sullivan, China's rabies vaccine market is expected to reach 14.8 billion yuan by 2030, and the company's products are expected to become the first choice of vaccination institutions.

https://finance.eastmoney.com/a/202503123343370483.html